30-Day Pilot Study: Ozone Therapy Shows Measurable Molecular Changes in Prostate Health
New pilot data from Doctors Studio, in collaboration with Oxford BioDynamics, suggest that intraprostatic ozone therapy may shift key prostate-related molecular markers in as little as 30 days, as measured by the EpiSwitch® Prostate Cancer Detection (PSE) blood test.
Snapshot of the Results
In this small, real-world pilot of 10 men (ages 54–76), we observed the following 30-day changes after a single intraprostatic ozone treatment:
average reduction in PSE probability score
of men showed decreases in PSE probability
average PSA decrease (after statistical adjustment for an outlier)
These are early findings from a small, uncontrolled pilot—but they suggest that ozone therapy may be able to nudge prostate-related molecular patterns in a more favorable direction over a short time frame.
What This Study Looked At
Design
• Type: Pre-/post pilot evaluation
• Timeline: Baseline bloodwork, intraprostatic ozone treatment, repeat bloodwork at 30 days
• Location: Doctors Studio (Boca Raton, FL) in collaboration with Oxford BioDynamics (UK)
Participants
• Number of participants: 10 men
• Age range: 54–76 years
This was intentionally a small, focused pilot designed to see if there were any signal of molecular change worth studying further.
Intervention
Each participant received:
• Intraprostatic ozone injection
The treatment was delivered directly into the prostate using established ozone therapy techniques.
What We Measured
Blood samples were collected before the procedure and again 30 days later, and analyzed for:
• EpiSwitch® PSE probability score:
A 3D genomic (epigenomic) blood test that estimates the probability of clinically significant prostate cancer.
• PSA (prostate-specific antigen) levels
• Multivariate pattern analysis (LDA):
To visualize whether pre- and post-treatment molecular profiles clustered differently.
What Is the EpiSwitch® PSE Test?
Traditional PSA testing can be helpful, but it can also be noisy leading to false alarms and, in some cases, unnecessary biopsies.
The EpiSwitch® Prostate Cancer Detection (PSE) Test:
• Is a validated blood test that measures 3D genomic conformations (how DNA folds and organizes in 3D space).
• Has reported 94% accuracy for detecting clinically significant prostate cancer in prior studies.
• Helps refine risk assessment when PSA and imaging leave unanswered questions.
• Can be used to track molecular changes over time, not just static snapshots.
In this pilot, we used PSE to see whether ozone therapy could influence these prostate-related molecular signals over a short, 30-day window.
Why This Matters
Men are often left in limbo:
• PSA is elevated or fluctuating…
• Imaging may be inconclusive…
• Biopsy may feel too aggressive—or has already been done and questions remain.
The combination of ozone therapy and PSE testing offers a potential way to:
• See whether an intervention is actually moving biology in the right direction, not just chasing PSA.
• Gain short-interval feedback (30 days) instead of waiting months or years.
• Add a molecular lens to complement PSA, MRI, and biopsy—not replace them.
“Men deserve clear, data-driven feedback on whether an intervention is moving their biology in the right direction. These early findings suggest measurable, short-interval molecular shifts—and justify larger, controlled studies.”
Key Findings in Plain Language
- Molecular Risk Scores Shifted Downward
- On average, PSE probability scores dropped by 31% after ozone therapy (statistically significant with p = 0.045).
- 8 out of 10 men (80%) showed a lower PSE probability at 30 days.
- Two men moved from a “high” PSE classification to a “low” classification in that short period.
This suggests that something about the intervention was associated with a measurable shift in prostate-related molecular risk signals.
2. PSA Trends Were Directionally Favorable
• PSA values decreased by about 20% on average after removing one statistical outlier.
PSA is only one piece of the puzzle, but seeing PSA and PSE move in a similar direction is encouraging.
- Molecular “Signature” Patterns Changed
Advanced analytics (LDA) showed:
- A clear separation between pre- and post-treatment molecular profiles, meaning the epigenomic “landscape” of the prostate-related markers looked different 30 days after ozone therapy.
This implies a coordinated shift in the underlying 3D genomic signatures linked to prostate biology and cancer risk.
Who Conducted the Study?
This research was a collaboration between:
- Doctors Studio (Boca Raton, FL)
- Oxford BioDynamics, Inc. (United Kingdom)
Jennifer Wright, ANP-C, MSN
Project Leader
Joe Abdo, PhD
Researcher
DO
For Media & Professional Inquiries
For interviews, speaking requests, or questions about this study:
Media Contact
Email: [email protected]
Phone: +1 (940) 283-6858
Read the Full Research Paper
If you’re a clinician, researcher, or an informed patient who wants to dive into the full methodology, statistics, and figures, you can access the complete paper here:
This page is for educational and informational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment. If you’d like to explore a personalized, root-cause approach to your prostate health, you can book a ProstaGen Assessment with our team at Doctors Studio.